-
1
-
-
15644363454
-
Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
-
DOI 10.1126/science.279.5350.577
-
Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279:577-580. (Pubitemid 28067289)
-
(1998)
Science
, vol.279
, Issue.5350
, pp. 577-580
-
-
Hirota, S.1
Isozaki, K.2
Moriyama, Y.3
Hashimoto, K.4
Nishida, T.5
Ishiguro, S.6
Kawano, K.7
Hanada, M.8
Kurata, A.9
Takeda, M.10
Tunio, G.M.11
Matsuzawa, Y.12
Kanakura, Y.13
Shinomura, Y.14
Kitamura, Y.15
-
2
-
-
0642368571
-
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
-
Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21:4342-4349.
-
(2003)
J Clin Oncol
, vol.21
, pp. 4342-4349
-
-
Heinrich, M.C.1
Corless, C.L.2
Demetri, G.D.3
-
3
-
-
0344667592
-
A two-arm phase II study of temozo-lomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas
-
Trent JC, Beach J, Burgess MA, et al. A two-arm phase II study of temozo-lomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 2003; 98:2693-2699.
-
(2003)
Cancer
, vol.98
, pp. 2693-2699
-
-
Trent, J.C.1
Beach, J.2
Burgess, M.A.3
-
4
-
-
20844433223
-
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial
-
Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364:1127-1134.
-
(2004)
Lancet
, vol.364
, pp. 1127-1134
-
-
Verweij, J.1
Casali, P.G.2
Zalcberg, J.3
-
5
-
-
0035810148
-
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
-
Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344:1052-1056.
-
(2001)
N Engl J Med
, vol.344
, pp. 1052-1056
-
-
Joensuu, H.1
Roberts, P.J.2
Sarlomo-Rikala, M.3
-
6
-
-
0036769721
-
Update of phase i study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: A report of the EORTC Soft Tissue and Bone Sarcoma Group
-
van Oosterom AT, Judson IR, Verweij J, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002; 38 (Suppl 5):S83-S87.
-
(2002)
Eur J Cancer
, vol.38
, Issue.SUPPL. 5
-
-
Van Oosterom, A.T.1
Judson, I.R.2
Verweij, J.3
-
7
-
-
39149127634
-
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
-
BlankeCD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26:626-632.
-
(2008)
J Clin Oncol
, vol.26
, pp. 626-632
-
-
Blankecd Rankin, C.1
Demetri, G.D.2
-
8
-
-
39149123549
-
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT
-
DOI 10.1200/JCO.2007.13.4403
-
Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26:620-625. (Pubitemid 351264357)
-
(2008)
Journal of Clinical Oncology
, vol.26
, Issue.4
, pp. 620-625
-
-
Blanke, C.D.1
Demetri, G.D.2
Von Mehren, M.3
Heinrich, M.C.4
Eisenberg, B.5
Fletcher, J.A.6
Corless, C.L.7
Fletcher, C.D.M.8
Roberts, P.J.9
Heinz, D.10
Wehre, E.11
Nikolova, Z.12
Joensuu, H.13
-
9
-
-
0033984319
-
Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival
-
DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231:51-58.
-
(2000)
Ann Surg
, vol.231
, pp. 51-58
-
-
Dematteo, R.P.1
Lewis, J.J.2
Leung, D.3
-
10
-
-
62849096370
-
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A rando mised, double-blind, placebo-controlled trial
-
Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a rando mised, double-blind, placebo-controlled trial. Lancet 2009; 373:1097-1104.
-
(2009)
Lancet
, vol.373
, pp. 1097-1104
-
-
Dematteo, R.P.1
Ballman, K.V.2
Antonescu, C.R.3
-
11
-
-
77953958051
-
-
Efficacy of adjuvant imatinib mesylate following complete resection of localized primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the U.S. Intergroup phase II trial ACOSOG Z9000 [abstract]
-
DeMatteo RP, Owzar K, Antonescu CR, et al. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the U.S. Intergroup phase II trial ACOSOG Z9000 [abstract]. American Society of Clinical Oncology (ASCO) 2008 Gastrointestinal Cancers Symposium; 2008.
-
(2008)
American Society of Clinical Oncology (ASCO) 2008 Gastrointestinal Cancers Symposium
-
-
Dematteo, R.P.1
Owzar, K.2
Antonescu, C.R.3
-
12
-
-
23844507560
-
Adjuvant imatinib mesylate in pa tients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: Safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000
-
American College of Surgeons Oncology Group (ACOSOG)
-
DeMatteo RP, Antonescu CR, Chadaram V, et al., American College of Surgeons Oncology Group (ACOSOG). Adjuvant imatinib mesylate in pa tients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000. J Clin Oncol 2005; 23 (16 Suppl):9009.
-
(2005)
J Clin Oncol
, vol.23
, Issue.16 SUPPL.
, pp. 9009
-
-
Dematteo, R.P.1
Antonescu, C.R.2
Chadaram, V.3
-
13
-
-
77952503219
-
A phase II study of imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors
-
[abstract #e21515]
-
Kang B, Lee J, Ryu M, et al. A phase II study of imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors [abstract #e21515]. J Clin Oncol 2009; 27 (Suppl).
-
(2009)
J Clin Oncol
, vol.27
, Issue.SUPPL.
-
-
Kang, B.1
Lee, J.2
Ryu, M.3
-
14
-
-
62149141753
-
A randomized, phase II study of preoperative plus postoperative imatinib in GIST: Evidence of rapid radio graphic response and temporal induction of tumor cell apoptosis
-
McAuliffe JC, Hunt KK, Lazar AJ, et al. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radio graphic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol 2009; 16:910-919.
-
(2009)
Ann Surg Oncol
, vol.16
, pp. 910-919
-
-
McAuliffe, J.C.1
Hunt, K.K.2
Lazar, A.J.3
-
15
-
-
58149399145
-
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent oper able gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665
-
Eisenberg BL, Harris J, BlankeCD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent oper able gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009; 99:42-47.
-
(2009)
J Surg Oncol
, vol.99
, pp. 42-47
-
-
Eisenberg, B.L.1
Harris, J.2
Blankecd3
-
16
-
-
33749263716
-
Perforated GIST of the small intestine as a rare cause of acute abdomen: Surgical treatment and adjuvant therapy. Case report
-
Efremidou EI, Liratzopoulos N, Papageorgiou MS, et al. Perforated GIST of the small intestine as a rare cause of acute abdomen: surgical treatment and adjuvant therapy. Case report. J Gastrointestin Liver Dis 2006; 15:297-299.
-
(2006)
J Gastrointestin Liver Dis
, vol.15
, pp. 297-299
-
-
Efremidou, E.I.1
Liratzopoulos, N.2
Papageorgiou, M.S.3
-
17
-
-
34547493419
-
Primary omental gastrointestinal stromal tumor (GIST)
-
Todoroki T, Sano T, Sakurai S, et al. Primary omental gastrointestinal stromal tumor (GIST). World J Surg Oncol 2007; 5:66.
-
(2007)
World J Surg Oncol
, vol.5
, pp. 66
-
-
Todoroki, T.1
Sano, T.2
Sakurai, S.3
-
18
-
-
44949165555
-
A malignant omental extra-gastrointestinal stromal tumor on a young man: A case report and review of the literature
-
Castillo-Sang M, Mancho S, Tsang AW, et al. A malignant omental extra-gastrointestinal stromal tumor on a young man: a case report and review of the literature. World J Surg Oncol 2008; 6:50.
-
(2008)
World J Surg Oncol
, vol.6
, pp. 50
-
-
Castillo-Sang, M.1
Mancho, S.2
Tsang, A.W.3
-
19
-
-
0042978501
-
Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: A centre-based study of 17 patients
-
Bumming P, Andersson J, Meis-Kindblom JM, et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer 2003; 89:460-464.
-
(2003)
Br J Cancer
, vol.89
, pp. 460-464
-
-
Bumming, P.1
Andersson, J.2
Meis-Kindblom, J.M.3
-
20
-
-
34249791491
-
Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)
-
Nilsson B, Sjolund K, Kindblom LG, et al. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer 2007; 96:1656-1658.
-
(2007)
Br J Cancer
, vol.96
, pp. 1656-1658
-
-
Nilsson, B.1
Sjolund, K.2
Kindblom, L.G.3
-
21
-
-
32944465148
-
A case of Giant GIST of the stomach successfully treated with imatinib mesylate neoadjuvant therapy and followed postoperatively
-
Okuda H, Tanaka H, Ueno M, et al. A case of Giant GIST of the stomach successfully treated with imatinib mesylate neoadjuvant therapy and followed postoperatively. Gan To Kagaku Ryoho 2005; 32:1941-1944.
-
(2005)
Gan to Kagaku Ryoho
, vol.32
, pp. 1941-1944
-
-
Okuda, H.1
Tanaka, H.2
Ueno, M.3
-
22
-
-
67649130820
-
Molecularly targeted therapy and radiotherapy in the management of localized gastrointestinal stromal tumor (GIST) of the rectum: A case report
-
Ciresa M, D'Angelillo RM, Ramella S, et al. Molecularly targeted therapy and radiotherapy in the management of localized gastrointestinal stromal tumor (GIST) of the rectum: a case report. Tumori 2009; 95:236-239.
-
(2009)
Tumori
, vol.95
, pp. 236-239
-
-
Ciresa, M.1
D'Angelillo, R.M.2
Ramella, S.3
-
23
-
-
67651253137
-
Imatinib mesylate neoadjuvant treatment for rectal malignant gastrointestinal stromal tumor
-
Hou YY, Zhou Y, Lu SH, et al. Imatinib mesylate neoadjuvant treatment for rectal malignant gastrointestinal stromal tumor. World J Gastroenterol 2009; 15:1910-1913.
-
(2009)
World J Gastroenterol
, vol.15
, pp. 1910-1913
-
-
Hou, Y.Y.1
Zhou, Y.2
Lu, S.H.3
-
24
-
-
79959798391
-
Successful resection of an advanced gastrointestinal stromal tumor by neoadjuvant chemotherapy with imatinib: A case report
-
Nakajima S, Sonoda K, Kadokawa Y, et al. Successful resection of an advanced gastrointestinal stromal tumor by neoadjuvant chemotherapy with imatinib: a case report. Gan To Kagaku Ryoho 2009; 36:2645-2648.
-
(2009)
Gan to Kagaku Ryoho
, vol.36
, pp. 2645-2648
-
-
Nakajima, S.1
Sonoda, K.2
Kadokawa, Y.3
-
25
-
-
33845633389
-
Surgical resection of gastrointestinal stromal tumors after treatment with imatinib
-
Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007; 14:14-24.
-
(2007)
Ann Surg Oncol
, vol.14
, pp. 14-24
-
-
Andtbacka, R.H.1
Ng, C.S.2
Scaife, C.L.3
-
26
-
-
34247610583
-
Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor
-
DeMatteo RP, Maki RG, Singer S, et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007; 245:347-352.
-
(2007)
Ann Surg
, vol.245
, pp. 347-352
-
-
Dematteo, R.P.1
Maki, R.G.2
Singer, S.3
-
27
-
-
77951810587
-
Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST)
-
[abstract #10550]
-
Hohenberger P, Oladeji O, Licht T, et al. Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST) [abstract #10550]. J Clin Oncol 2009; 27 (15 Suppl).
-
(2009)
J Clin Oncol
, vol.27
, Issue.15 SUPPL.
-
-
Hohenberger, P.1
Oladeji, O.2
Licht, T.3
-
28
-
-
76649092813
-
Neoadjuvant imatinib in patients with locally advanced GIST in the prospective BFR14 trial
-
[abstract #10551]
-
Cassier PA, Blesius AA, Perol D, et al. Neoadjuvant imatinib in patients with locally advanced GIST in the prospective BFR14 trial [abstract #10551]. J Clin Oncol 2009; 27 (15 Suppl).
-
(2009)
J Clin Oncol
, vol.27
, Issue.15 SUPPL.
-
-
Cassier, P.A.1
Blesius, A.A.2
Perol, D.3
-
29
-
-
68849122493
-
Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor
-
Rink L, Skorobogatko Y, Kossenkov AV, et al. Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor. Mol Cancer Ther 2009; 8:2172-2182.
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 2172-2182
-
-
Rink, L.1
Skorobogatko, Y.2
Kossenkov, A.V.3
-
30
-
-
33750076675
-
Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor
-
Trent JC, Ramdas L, Dupart J, et al. Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor. Cancer 2006; 107:1898-1908.
-
(2006)
Cancer
, vol.107
, pp. 1898-1908
-
-
Trent, J.C.1
Ramdas, L.2
Dupart, J.3
-
31
-
-
36749006701
-
Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate
-
McAuliffe JC, Lazar AJ, Yang D, et al. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate. Clin Cancer Res 2007; 13 (22 Pt 1):6727-6734.
-
(2007)
Clin Cancer Res
, vol.13
, Issue.22 PART 1
, pp. 6727-6734
-
-
McAuliffe, J.C.1
Lazar, A.J.2
Yang, D.3
-
32
-
-
34447557780
-
NCCN Task Force report: Management of patients with gastrointestinal stromal tumor (GIST): Update of the NCCN clinical practice guidelines
-
quiz S30
-
Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST): update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007; 5 (Suppl 2):S1-S29; quiz S30.
-
(2007)
J Natl Compr Canc Netw
, vol.5
, Issue.SUPPL. 2
-
-
Demetri, G.D.1
Benjamin, R.S.2
Blanke, C.D.3
-
33
-
-
43049167312
-
Imatinib mesilate for the treatment of gastrointestinal stromal tumour
-
Cassier PA, Dufresne A, Arifi S, et al. Imatinib mesilate for the treatment of gastrointestinal stromal tumour. Expert Opin Pharmacother 2008; 9:1211-1222.
-
(2008)
Expert Opin Pharmacother
, vol.9
, pp. 1211-1222
-
-
Cassier, P.A.1
Dufresne, A.2
Arifi, S.3
-
34
-
-
61449120255
-
Controversies in the surgical management of GIST in the era of imatinib
-
Raut CP, Bertagnolli MM. Controversies in the surgical management of GIST in the era of imatinib. Oncology (Williston Park) 2009; 23:69; 74-76.
-
(2009)
Oncology (Williston Park)
, vol.23-69
, pp. 74-76
-
-
Raut, C.P.1
Bertagnolli, M.M.2
-
35
-
-
62849115588
-
Adjuvant treatment of GIST with imatinib: Solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group
-
the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS)
-
Gronchi A, Judson I, Nishida T, et al. Adjuvant treatment of GIST with imatinib: solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS). Eur J Cancer 2009; 45:1103-1106.
-
(2009)
Eur J Cancer
, vol.45
, pp. 1103-1106
-
-
Gronchi, A.1
Judson, I.2
Nishida, T.3
-
36
-
-
0036301722
-
Diagnosis of gastrointestinal stromal tumors: A consensus approach
-
DOI 10.1053/hupa.2002.123545
-
Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33:459-465. (Pubitemid 34747864)
-
(2002)
Human Pathology
, vol.33
, Issue.5
, pp. 459-465
-
-
Fletcher, C.D.M.1
Berman, J.J.2
Corless, C.3
Gorstein, F.4
Lasota, J.5
Longley B.Jack6
Miettinen, M.7
O'Leary, T.J.8
Remotti, H.9
Rubin, B.P.10
Shmookler, B.11
Sobin, L.H.12
Weiss, S.W.13
-
37
-
-
33749459756
-
Gastrointestinal stromal tumors: Review on morphology, molecular pathology, prognosis, and differential diagnosis
-
Miettinen M, LasotaJ. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006; 130:1466-1478.
-
(2006)
Arch Pathol Lab Med
, vol.130
, pp. 1466-1478
-
-
Miettinen, M.1
Lasota, J.2
-
38
-
-
71449088757
-
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: A retrospective analysis
-
Gold JS, Gonen M, Gutierrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009; 10:1045-1052.
-
(2009)
Lancet Oncol
, vol.10
, pp. 1045-1052
-
-
Gold, J.S.1
Gonen, M.2
Gutierrez, A.3
-
39
-
-
73949137372
-
Detection of c-KIT and PDGFRA gene mutations in gastrointestinal stromal tumors: Comparison of DHPLC and DNA sequencing methods using a single population-based cohort
-
Battochio A, Mohammed S, Winthrop D, et al. Detection of c-KIT and PDGFRA gene mutations in gastrointestinal stromal tumors: comparison of DHPLC and DNA sequencing methods using a single population-based cohort. Am J Clin Pathol 133: 149-155.
-
Am J Clin Pathol
, vol.133
, pp. 149-155
-
-
Battochio, A.1
Mohammed, S.2
Winthrop, D.3
|